Articles related to Hematology

“This guideline is a road map to help clinicians navigate these advances for the safest and most effective approaches to care.” — Mark A. Creager, MD, Dartmouth Health

The primary study outcome was a composite of serious bleeding events leading to hospitalization. Secondary study outcomes included composites of stroke or systemic embolism.

“CHIP, especially non-DNMT3A CHIP, was independently associated with incident HF. Future research should explore the gene-specific mechanisms by which CHIP variants promote HF in humans.” — Study Authors, JAMA Cardiology

First-line treatment with IV iron dextran is the cost-effective strategy for managing IDA in women with HMB at commonly accepted willingness-to-pay thresholds.

“Although historically grouped together, viral-associated PCNSL subtypes are biologically distinct diseases. Each escapes immune control through a different mechanism, creating fundamentally different tumor microenvironments.” – Melinda Burgess, Researcher from the Department of Haematology at Princess Alexandra Hospital

Thrombotic events occurred earlier with Andexxa than usual care (median of 3.5 days vs 16 days). Fifty-three percent of Andexxa-treated patients who experienced a thrombotic event had the event during the first 3 days.